NEOLISE Longevity CJC-1295 Reviews and Complaints 2026: A Comprehensive Analysis
NEOLISE Longevity CJC-1295 :NEOLISE Longevity is a peptide supplement product marketed as containing CJC-1295, a synthetic growth hormone-releasing hormone (GHRH) analog promoted for anti-aging, body composition, recovery, and longevity. The product is distributed through the MaxBounty CPA network with a $300 per lead payout, and is targeted at biohackers, longevity enthusiasts, and adults aged 25–55 interested in hormone optimization and healthy aging. Notably, the offer explicitly prohibits fake news layouts, fabricated endorsements, before-and-after imagery, and any claim of guaranteed outcomes — restrictions that suggest awareness of prior compliance issues in this marketing vertical.
However, there is a critical distinction that must be made up front: NEOLISE Longevity is a compounded peptide product, not an FDA-approved medication. CJC-1295 is not approved for human use in the United States, has no published Phase 1 human safety data, and lacks controlled human efficacy trials for any consumer indication. The FDA has classified CJC-1295 as a Category 2 bulk drug substance, which prohibits licensed compounding pharmacies from using it in compounded medications. The peptide is banned by the World Anti-Doping Agency.
Review Summary Box
| Feature | Details |
|---|---|
| Overall Rating | 2.0 / 5 ⭐ |
| Best For | No reliable recommendation — significant safety and regulatory concerns |
| Product Type | Compounded peptide supplement (CJC-1295) |
| Active Ingredient | CJC-1295 (GHRH analog, with DAC) |
| Format | Not fully disclosed (likely injectable, based on peptide category) |
| Price | Not publicly disclosed |
| Money-Back Guarantee | Not disclosed |
| Regulatory Status | Not FDA-approved for human use; FDA Category 2 bulk drug substance |
| WADA Status | Banned — prohibited under Category S2 |
| Distribution | MaxBounty CPA network; $300 per lead payout |
| Target Audience | Biohackers, longevity enthusiasts aged 25–55 |
| Restrictions on Affiliates | No fake news, no fabricated endorsements, no guaranteed outcomes |
What Is NEOLISE Longevity?
NEOLISE Longevity is marketed as a premium peptide supplement containing CJC-1295, a synthetic analog of growth hormone-releasing hormone (GHRH). The product is positioned for anti-aging, body composition improvement, recovery, and longevity.
The CJC-1295 Compound
CJC-1295 is a long-acting GHRH analog that stimulates the pituitary gland to release growth hormone (GH), which in turn increases insulin-like growth factor-1 (IGF-1) levels. Two versions exist:
| Version | Half-Life | Dosing Frequency | GH Pulse Pattern |
|---|---|---|---|
| CJC-1295 with DAC | ~5.8–8.1 days | 1–2 injections per week | Blunted, sustained GH elevation |
| CJC-1295 without DAC (Mod GRF 1-29) | ~30 minutes | 1–3 injections per day | Mimics natural pulsatile GH release |
The DAC (Drug Affinity Complex) modification allows CJC-1295 to covalently bind to endogenous albumin once injected, extending its half-life to a duration similar to that of albumin. This albumin interaction creates a circulating depot that significantly prolongs the peptide’s elimination half-life.
The Marketing Context
NEOLISE Longevity is distributed through the MaxBounty affiliate network, a performance-based CPA platform. The offer pays $300 per qualified lead, with conversions only counted after payment is received, provider approval is granted, the 48-hour cancellation window has passed, and the medication has shipped. This multi-step approval process and high payout are typical of high-ticket telehealth or compounded medication offers.
The offer restrictions are notable: affiliates are prohibited from using “fake news layouts or fabricated endorsements, before and after imagery, any claim of guaranteed outcomes, and any depiction of a provider or clinician who isn’t real”. These restrictions were likely imposed because this marketing vertical has a history of deceptive practices.
The Critical Safety Problem: No Human Safety Data
The most important fact about NEOLISE Longevity is not about the specific product — it is about the ingredient itself. CJC-1295 has not been approved for human use, and there is a profound lack of human safety and efficacy data.
What the Regulatory and Medical Authorities Say
| Source | Finding |
|---|---|
| FDA (2026) | CJC-1295 is a Category 2 bulk drug substance, prohibited for use in compounding by licensed pharmacies |
| FDA | “CJC-1295 in its various forms is a synthetic analogue of GHRH” and each related BDS was “not well-characterized” |
| FDA | Concerns about “immunogenicity, aggregation, peptide-related impurities, and inadequate safety information” |
| FDA | Nonclinical toxicological studies “raise safety concerns for potential clinical uses of CJC-1295 DAC in any form,” including local injection site safety signals characterized by hemorrhage |
| UCLA Health review (2026) | Reviewed 565 studies on six peptides; “essentially no studies demonstrating significant clinical benefits for musculoskeletal conditions in humans” |
| Medical literature | “No high-quality, long-term human studies demonstrating improved healthspan or survival” |
| WADA | CJC-1295 is banned — prohibited under Category S2 (peptide hormones, growth factors, and related substances) |
The Phase 2 Trial Death
CJC-1295 was under Phase 2 investigation for the treatment of lipodystrophy and GH deficiency. The trial was discontinued after an enrolled patient died from myocardial infarction. While the attending physician judged the death unrelated to the drug, the development program was shelved.
The Cancer Risk Signal
Prospective observational studies of endogenous IGF-1 concentrations have documented associations with increased risk of colorectal, prostate, and breast cancer. These are associations between naturally occurring variation in IGF-1 levels and cancer incidence. Whether pharmacologically elevating IGF-1 through exogenous GH secretagogues in healthy adults produces equivalent or greater oncological risk has not been established in interventional trials. The hypothesis cannot currently be excluded.
The 2026 review of performance-enhancing peptides modulating the GH-IGF-1 axis specifically concludes that “regulatory and clinical concern regarding sustained endocrine manipulation in healthy individuals is growing and that the risk-benefit ratio for healthy consumers remains formally undefined”.
Real-World Adverse Effects
Bryan Johnson, the longevity entrepreneur who publicly documents his health experiments, reported the following after using CJC-1295:
| Marker | Change |
|---|---|
| Morning fasted blood sugar | Increased 20% |
| Stress hormone | Increased 12% |
| REM sleep | Decreased 23% |
| Pancreatic workload | Increased 53% |
| Insulin resistance | Increased |
These are not theoretical risks. They are documented physiological changes in a healthy adult using the compound.
What the Research Actually Shows
Human Pharmacodynamic Findings
In randomised, placebo-controlled studies involving healthy adults, CJC-1295 produced substantial and prolonged hormonal effects:
| Parameter | Effect |
|---|---|
| Mean GH concentrations | Increased 2- to 10-fold for six days or longer |
| Mean IGF-1 concentrations | Increased 1.5- to 3-fold for 9–11 days |
| Estimated half-life | 5.8–8.1 days |
| IGF-1 after repeated doses | Remained elevated above baseline for up to 28 days |
These are genuine human pharmacodynamic findings. They demonstrate that CJC-1295 can alter the GH/IGF-1 axis. They do not demonstrate clinical benefit for anti-aging, performance enhancement, injury recovery, cognitive improvement, or any other consumer indication.
The UCLA Review
A UCLA Health review of 565 studies on six popular unapproved peptides — BPC-157, TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu — found little evidence that they provide meaningful benefits. Key findings:
- More than two-thirds of the studies were conducted only in animals
- The animal studies found promising but variable effects on tendon, muscle, bone, and ligament healing
- The researchers found essentially no studies demonstrating significant clinical benefits for musculoskeletal conditions in humans
- A handful of human studies found modest improvements at best for non-orthopedic indications
- Studies reporting positive clinical findings generally lacked robust controls or rigorous study designs
- The supplements are not regulated or vetted by the FDA, creating uncertainty about their contents and manufacturing
The researchers concluded that marketing claims about peptides are far ahead of the science.
Complete Safety Profile
Reported Side Effects
| Side Effect | Frequency | Source |
|---|---|---|
| Injection site reactions | 10–30% | Erythema, induration, transient discomfort |
| Flushing | 1–10% | Transient facial flushing shortly after injection |
| Water retention | 1–10% | Puffiness in face, hands, and feet, particularly in the morning |
| Headache | Common | Mild to moderate, most common during the first 1–2 weeks |
| Increased appetite | Reported | GH-mediated effect |
| Nausea | Occasional | Mild |
| Numbness and tingling in hands | Reported | Carpal tunnel-like symptoms from fluid retention |
| Vivid dreams | Reported | — |
| Joint stiffness | Occasional | — |
| Insulin resistance | Reported | At supraphysiologic doses |
| Dysglycaemia | Reported | Blood sugar changes |
| Prolactin and cortisol elevations | Reported | Endocrine disturbances |
| Mild gynecomastia | Rare | — |
The Water Retention and Fluid Syndrome
Sustained IGF-1 elevation can cause swelling and fluid retention, and has been linked to hormonal imbalances, disruption to ovarian function, and a higher risk of miscarriage. This is particularly concerning for women considering these peptides.
The Long-Term Cancer Risk
Chronically elevated IGF-1 carries a plausible, mechanism-supported cancer risk that no CJC-1295 trial has been long enough or large enough to detect or rule out. Cancer cells have receptors for IGF-1, and high IGF-1 could theoretically act as “fuel” for a tumor. While there is no evidence that CJC-1295 directly causes cancer (it does not mutate DNA), the sustained elevation of IGF-1 remains a theoretical concern that cannot be dismissed.
Safety and Regulatory Considerations
Not FDA-Approved
CJC-1295 is not approved by the FDA for any human indication. It is not a dietary supplement, and it is not a compounded medication that falls within standard pharmacy practice. As of April 2026, CJC-1295 is classified as an FDA 503A Category 2 bulk drug substance, which prohibits licensed compounding pharmacies in the United States from using it in compounded medications.
This means that any CJC-1295 product sold to consumers — including NEOLISE Longevity — is being sold outside the regulated pharmaceutical supply chain.
Banned by WADA
CJC-1295 is prohibited at all times by the World Anti-Doping Agency under Category S2 (peptide hormones, growth factors, and related substances). Any athlete subject to drug testing who uses NEOLISE Longevity would face a doping violation.
Unknown Long-Term Safety
The long-term safety profile of CJC-1295 in humans is completely unknown. There are no long-term studies, no Phase 1 safety data, and no post-market surveillance. The FDA’s own review concluded that CJC-1295 forms are “not well-characterized” and that nonclinical toxicological studies “raise safety concerns.”
Who Should Avoid
- Athletes subject to drug testing — CJC-1295 is WADA-banned
- Anyone with a history of cancer — IGF-1 elevation is a theoretical cancer risk
- Women of reproductive age — linked to hormonal imbalances and miscarriage risk
- Anyone with insulin resistance or diabetes — CJC-1295 can worsen dysglycaemia
- Pregnant or nursing women — safety not established
- Anyone taking prescription medications — no interaction data exists
- Anyone who wants FDA-approved, clinically tested products — CJC-1295 does not qualify
Pricing and Where to Buy
Pricing information for NEOLISE Longevity is not publicly disclosed. The product is sold through affiliate marketing channels, and the offer details do not include consumer pricing. The MaxBounty offer page lists a payout of $300 per lead but does not disclose the retail price.
Critical Warning: Because this product is distributed through CPA affiliate networks with high payouts, consumers should exercise extreme caution. High-payout offers are often associated with aggressive marketing, and the lack of independent reviews means there is no way to verify the product’s quality, safety, or whether refunds are honored.
Final Verdict
Strengths
- None supported by human clinical evidence. The product contains a peptide that has not been approved for human use and lacks basic safety data. There are no independent reviews, no published human trials for consumer indications, and no verifiable customer feedback.
Weaknesses
- ⚠️ Not FDA-approved — CJC-1295 is not approved for human use
- ⚠️ FDA Category 2 bulk drug substance — prohibited for use in compounding by licensed pharmacies
- ⚠️ Phase 2 trial discontinued after participant death from myocardial infarction
- ⚠️ No human safety data — no Phase 1 trials, no controlled efficacy studies for consumer indications
- ⚠️ Cancer risk signal — IGF-1 elevation is associated with colorectal, prostate, and breast cancer
- ⚠️ Documented adverse metabolic effects — increased blood sugar, insulin resistance, and pancreatic workload in a documented user
- ⚠️ Banned by WADA — prohibited for athletes
- ⚠️ $300 per lead payout — high affiliate incentive for aggressive marketing
- ⚠️ No independent reviews — no Trustpilot, Reddit, or consumer feedback
- ⚠️ No disclosed pricing or refund policy
- ⚠️ UCLA review found “essentially no studies” demonstrating clinical benefits in humans
Who May Benefit
Based on the available evidence, no one should use this product without a physician’s supervision and a clear understanding of the risks. The peptide is not approved for human use, has no established safety profile, and carries documented adverse metabolic effects and a theoretical cancer risk.
Who Should Avoid
Everyone. The combination of an unapproved peptide, absent human safety data, WADA prohibition, a discontinued Phase 2 trial following a participant death, documented metabolic harms, and high-pressure affiliate marketing makes this a high-risk product. If you are interested in longevity or healthy aging, consult a physician about evidence-based interventions with established safety profiles — such as exercise, nutrition, sleep optimization, and FDA-approved therapies where indicated.
Overall Recommendation
Rating: 2.0 out of 5 Stars
NEOLISE Longevity contains CJC-1295, a peptide that is not FDA-approved for human use and has no published human safety or efficacy data for consumer indications. The FDA has classified CJC-1295 as a Category 2 bulk drug substance, prohibiting its use in compounding. The Phase 2 clinical trial was discontinued after a participant died from myocardial infarction. Human pharmacodynamic studies show that CJC-1295 alters the GH/IGF-1 axis, but they do not demonstrate clinical benefit for anti-aging, performance, or recovery. The UCLA Health review of 565 studies found “essentially no studies demonstrating significant clinical benefits” in humans for this peptide class. For anyone considering peptide therapy, the safer path is to consult a physician about FDA-approved treatments with established safety profiles.
Frequently Asked Questions
What is NEOLISE Longevity?
NEOLISE Longevity is a peptide supplement product marketed as containing CJC-1295, a synthetic GHRH analog promoted for anti-aging, body composition, and longevity. It is distributed through the MaxBounty CPA affiliate network.
Is CJC-1295 FDA-approved?
No. CJC-1295 is not approved by the FDA for any human indication. As of April 2026, it is classified as an FDA 503A Category 2 bulk drug substance, which prohibits licensed compounding pharmacies in the United States from using it in compounded medications.
Why was the CJC-1295 clinical trial discontinued?
ConjuChem advanced CJC-1295 DAC through Phase 2 clinical trials for adult growth hormone deficiency and lipodystrophy. Clinical development was discontinued following the death of a participant during a trial, reportedly due to a cardiovascular event (myocardial infarction).
Is NEOLISE Longevity safe?
There is no human safety data for CJC-1295 in healthy adults. The FDA has raised concerns about immunogenicity, aggregation, and peptide-related impurities. Documented adverse effects include water retention, joint stiffness, numbness, insulin resistance, dysglycaemia, and increased blood sugar. A theoretical cancer risk from sustained IGF-1 elevation cannot be excluded.
Why is CJC-1295 banned by WADA?
CJC-1295 is prohibited by the World Anti-Doping Agency under Category S2 (peptide hormones, growth factors, and related substances) because it is considered a performance-enhancing substance. It is banned at all times for athletes.
Can I buy NEOLISE Longevity?
NEOLISE Longevity is distributed through affiliate marketing channels. Pricing and availability are not publicly disclosed. Given the significant safety and regulatory concerns, purchase is not recommended.
What should I do instead?
If you are interested in longevity, healthy aging, or body composition improvements, consult a physician about evidence-based interventions with established safety profiles. These include structured exercise programs, nutrition optimization, sleep improvement, and FDA-approved therapies where clinically indicated. There are evidence-based options that do not involve unapproved peptides.
What did Bryan Johnson’s CJC-1295 experiment show?
Bryan Johnson, the longevity entrepreneur, reported that CJC-1295 increased his morning fasted blood sugar by 20%, increased stress hormone by 12%, decreased REM sleep by 23%, made his pancreas work 53% harder, and increased insulin resistance.
Is there any evidence CJC-1295 works for anti-aging?
Human pharmacodynamic studies show that CJC-1295 increases GH and IGF-1 levels. However, there is no clinical evidence that these hormonal changes translate into anti-aging benefits, improved healthspan, or extended lifespan. The UCLA Health review of 565 studies found “essentially no studies demonstrating significant clinical benefits” in humans.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. CJC-1295 is not FDA-approved for human use, is classified as an FDA Category 2 bulk drug substance, and is banned by WADA. Always consult a qualified healthcare professional before starting any new supplement or treatment, especially if you have existing health conditions, take medications, or are pregnant or nursing. Individual results may vary.
